Leading the way to a cure


Human and Mouse Monoclonal Antibodies Neutralizing Interferon-alpha to Treat SLE

Banchereau, Jacques, PhD

Baylor Institute for Immunology Research

Previous studies led by Dr. Banchereau provide strong evidence that interferon-alpha contributes to immune system abnormalities in children and adolescents with lupus. Research also suggests that interferon-alpha plays an important role in the development of lupus in adults. Dr. Banchereau and his colleagues are producing human and mouse antibodies that target interferon-alpha and block its effects on immune cells. They will identify the antibody that is most effective at “neutralizing” interferon-alpha and test the effects of this antibody in a mouse/human model of lupus created by transplanting immune cells from lupus patients into mice.

What this study means for people with lupus: Lupus in children is a particularly aggressive disease, and better, more specific, treatments with fewer side effects are urgently needed. Laboratory-produced antibodies that block the effects of interferon-alpha may provide more specific and effective therapy for lupus in both young people and adults.

1.5 million

people in the U.S. have Lupus.

172 million

dollars committed to lupus research by the Lupus Research Alliance.

We're walking across the United States to raise awareness and funds for lupus research.


Show your support by visiting the Lupus Research Alliance online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Blackbaud
nonprofit software